TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06789289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 injection
Description: TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC2938 injection Placebo
Description: TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.
Study: NCT06790082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-FAPI-46 PET/CT
Description: Patients with suspected pleural mesothelioma undergo FAPI PET/CT in addition to conventional imaging at primary staging.~The subgroup of patients undergoing anticancer treatment will undergo an additional FAPI PET/CT and FDG PET/CT after completing 2-3 series of anticancer treatment.
Study: NCT06789939

Intervention type: OTHER
Intervention: Train the trainer program for MPCC professionals
Description: The intervention will consist on a train the trainer program. 3 professionals from each MPCC will be trained by an educational team. They will then have to implement an IPEP (knowledge of the MPCC, participation in interprofessional MPCC activities, etc.) for students on placement in their MPCC.
Study: NCT06788886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Participate in walking routines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in walking routines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06788886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05389722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Specified dose on specified days
Study: NCT06041945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard, high-definition colonoscopy with the use of CADe assistance
Description: All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06041945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ
Description: All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ
Description: Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
Study: NCT06199219

Intervention type: OTHER
Group type: OTHER
Intervention: Sexual counseling, based on the extended (EX-PLISSIT)
Description: The EX-PLISSIT model is done in a cyclical manner. In other words, it is an interactive and repetitive model. All interventions must begin with Permission. Each stage of Limited Information, Special Recommendation and Intensive Therapy is supported by Allowing. Thus, the interaction between counselors and clients is improved (Taylor and Davis 2006; Punjani and Papathanasoglu, 2019).
Study: NCT06415045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study: NCT06788886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06630325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06191094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab Injection
Description: Pre-operative injection of bevacizumab appears to have mixed results in lowering post-operative vitreous hemorrhage. One potential reason is due to aspiration and removal of medication in the vitreous humor at the time of pars plana vitrectomy leading to less than anticipated results in controlling neovascularization and vitreous hemorrhage post-operatively. To avoid attenuation of our desired effect we plan to repeat faricimab injection post-operatively around week one.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham treatment
Description: Patients will be randomized 2:1 to receive either faricimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection
Study: NCT05912062

Intervention type: DRUG
Intervention: Trastuzumab (neoadjuvant)
Description: Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles

Intervention type: DRUG
Intervention: Pertuzumab (neoadjuvant)
Description: Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
Study: NCT06788886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Therapy
Description: Participate in breathing sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Therapy
Description: Participate in breathing sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Therapy
Description: Participate in breathing sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Therapy
Description: Participate in breathing sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Therapy
Description: Participate in breathing sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Therapy
Description: Participate in breathing sessions
Study: NCT06784934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroSky Mindfulness-Based Neurofeedback
Description: NeuroSky will monitor participants' brain response to the intervention and provide feedback based on the participants' performance. Neurofeedback Intervention: When practicing the mindfulness-based intervention, NeuroSky will provide instructions before beginning the sessions. Dr. Saul will assist with set up and answer any questions. The apps audio and visual feedback will assist the participants as they practice mindfulness meditation. Participants in the experimental group will practice for 10 minutes in the lab during Sessions 1 and 5 and then at home for 10-20 minutes daily for 4 weeks with weekly 10-minute virtual check-ins with Dr. Saul to ensure acceptability and feasibility. Dr. Saul will also monitor participants' progress using the secure participant portal and de-identified usernames available through NeuroSky.
Study: NCT06789536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training nurses to prescribe nicotine substitutes, to adapt doses and to transmit to the outpatient physician and/or nurse nurse to facilitate the continuation of treatment
Description: Nurses will undergo training sessions provided by the smoking cessation team to learn how to prescribe nicotine replacement therapy, adjust dosages, and forward a referral letter to the patient's primary care physician and/or community nurse for continuity of care. They will receive a dosage adjustment guide to share with patients. Upon completing the training, nurses will be authorized to prescribe nicotine replacement therapy using the hospital's prescription software.
Study: NCT06788418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wavelight Plus Alcon system
Description: Wavelight Plus Alcon system guided surgery for myopia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMILE
Description: Small Incision Lenticule Extraction surgery for myopia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICL
Description: Implantable Collamer Lens surgery for myopia
Study: NCT06784700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Participants will be positioned inside a massage chair for a 30-min, followed by an additional 30-minute period of lying down on a proper double bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Participants will be positioned inside a massage chair for a 30-min, followed by an additional 30-minute period of lying down on a proper double bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Participants will be positioned inside a massage chair for a 30-min, followed by an additional 30-minute period of lying down on a proper double bed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: Subjects will not receive any massage program; instead, they will be rested for 30 minutes on an automatic switch-off electric massage chair and subsequently lay down for an additional 30 minutes on a proper double bed;
Study: NCT06789900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Afinitor®)
Description: Oral dose of everolimus 5 mg once a week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Afinitor®)
Description: Oral dose of everolimus 5 mg once a week for 24 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Football Fitness Concept
Description: Structured hybrid exercise training via the football fitness concept organized as a super-vised group training at the University of Southern Denmark, Department of Sports Science and Clinical Biomechanics. Football Fitness concept is designed for participants with little prior experience with football and it is multifaceted training incorporating endurance training, high-intensity interval training (HIIT) and strength training. The training session lasts 60 minutes, and participants will receive two training sessions per week for 24 weeks. Each session is composed of 4 elements: a 15 min warm-up that includes strength and balance exercises, a 15 min period with technical pair-based drills, and a 30-min period with small-sided football drills
Study: NCT06789900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Football Fitness Concept
Description: Structured hybrid exercise training via the football fitness concept organized as a super-vised group training at the University of Southern Denmark, Department of Sports Science and Clinical Biomechanics. Football Fitness concept is designed for participants with little prior experience with football and it is multifaceted training incorporating endurance training, high-intensity interval training (HIIT) and strength training. The training session lasts 60 minutes, and participants will receive two training sessions per week for 24 weeks. Each session is composed of 4 elements: a 15 min warm-up that includes strength and balance exercises, a 15 min period with technical pair-based drills, and a 30-min period with small-sided football drills
Study: NCT06789315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF at a dose of 750 mg twice daily for a period of 28 days,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone at a dose of 40 mg for 28 days.
Study: NCT06789809

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise MRI
Description: Exercise stress MRI with ergometer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise MRI
Description: Exercise stress MRI with ergometer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise MRI
Description: Exercise stress MRI with ergometer
Study: NCT06790056

Intervention type: PROCEDURE
Intervention: duodenal ndoscopic bind ligation
Description: We will collect your basic demographics details like age, Sex, date of admission, Endoscopy (is a test to look inside your body) details of Site, size, number of lesion.~By EUS (Endoscopic ultrasound (EUS) combines two techniques - endoscopy and ultrasound - to help doctors see, evaluate and diagnose conditions in and near the gastrointestinal (GI) tract) details of layer of Duodenum involved, site/size/number of lesions.~We will collect your details of Duodenal endoscopic band ligation procedure to check feasibility, technical success.~You are requested to come for follow up for 3 months for endoscopy prodecure.
Study: NCT06788509

Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-75348780
Description: Participants from the parent study (75348780LYM1001 \[NCT04540796\]) who are deriving benefit from study treatment will continue to receive subcutaneous JNJ-75348780.

Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-67856633
Description: Participants from the parent studies (64264681LYM1002 \[NCT04657224\], 67856633LYM1002 \[NCT04876092\] and 67856633LYM1001 \[NCT03900598\]) who are deriving benefit from study treatment will continue to receive JNJ-67856633 orally.

Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-54179060
Description: Participants from the parent study (67856633LYM1002 \[NCT04876092\]) who are deriving benefit from study treatment will continue to receive JNJ-54179060 orally.

Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-64264681
Description: Participants from the parent studies (64264681LYM1001 \[NCT04210219\], 64264681LYM1002 \[NCT04657224\]) who are deriving benefit from study treatment will continue to receive JNJ-64264681 orally.

Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-74856665
Description: Participants from the parent study (74856665AML1001 \[NCT04609826\]) who are deriving benefit from study treatment will continue to receive JNJ-74856665 orally.

Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-70218902
Description: Participants from the parent study (70218902EDI1001 \[NCT04397276\]) who are deriving benefit from study treatment will continue to receive JNJ-70218902 orally.

Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-64619178
Description: Participants from the parent study (64619178EDI1001 \[NCT03573310\]) who are deriving benefit from study treatment will continue to receive JNJ-64619178 orally.
Study: NCT06788756

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with Cytarabine Injection
Description: placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with Cytarabine Injection
Description: placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Annamycin Injection in combination with Cytarabine Injection
Description: 190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Annamycin Injection in combination with Cytarabine Injection
Description: 230 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Annamycin for Injection in combination with Cytarabine Injection.
Description: optimal dosage regimen (as determined in Part A) of L Annamycin for Injection (190 mg/m2/day or 230 mg/m2/day) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 2 or 3, respectively, of Part A).
Study: NCT06789588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pharmacogenetic algorithm
Description: The dose predictor algorithm proposed in this work aims to maintain and quality treatment in an individualized and effective manner. In the routine use protocol, warfarin is prescribed based only on the INR collected within 5 days. The proposed intervention protocol is based on the patient's clinical and genetic factors, such as genetic polymorphisms, age, weight, height, race, use of amiodarone, statins, antifungals or antibiotics, tobacco use, clinical indication and what the RNI target.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinical treatment
Description: Patients with AF indicated for OAC therapy guided by institutional protocol.
Study: NCT06788678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVED
Description: MOVED includes 8 self-guided, web-based sessions administered over 4 weeks. Web-based sessions include 3 core components: (1) elicit moral elevation, (2) engage in reflection about moral elevation response, and (3) set a behavioral goal that is inspired by the moral elevation exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care Control
Description: A present-centered, nondirective intervention that aims to control for the nonspecific therapeutic effects of supportive care. In this case, the effects of engaging in regular web-based sessions that convey information about PTSD symptoms. Sessions will include psychoeducation materials about PTSD symptoms, functioning, and resources for dealing with related stressors. Key components of MOVED will be strictly excluded.
Study: NCT06788171

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy
Description: PULSAR (SBRT): A targeted radiation therapy delivering 5-10 Gy/fraction every 3 weeks (q3w) to the gross tumor volume (GTV), for 3 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.
Study: NCT05913947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
Study: NCT06788171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg, d1, q3w, 6 cycles.
Study: NCT06789978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Description: Prehospital extracorporeal cardiopulmonary resuscitation (ECPR)